Clinical Trial Detail

NCT ID NCT02714218
Title A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult

No variant requirements are available.